Is CeriBell, Inc. (CBLL) Among the Best Brain-Computer Interface Stocks to Buy?

CeriBell, Inc. (NASDAQ:CBLL) is among the Best Brain-Computer Interface Stocks.

On June 8, CeriBell, Inc. (NASDAQ:CBLL) reported a study published in Critical Care Medicine that higher AI-detected seizure burden is linked with increased odds of disability results at discharge. It analyzed 359 adult patients across three academic centers.

The company said patients with a peak seizure burden of at least 90% were 3.4 times more likely to experience death or severe disability compared to those with no seizure burden. Hence, the elevated burden directly leads to poorer functional outcomes.

The medtech firm revealed that risk develops with time. It stated that each additional hour of AI-detected seizure activity nearly doubled the odds of severe disability or death, noting an adjusted odds ratio of 1.98.

Lead author Josef Parvizi said the algorithm detects clinically relevant biomarkers with prognosis, underlining potential for earlier intervention.

CEO Jane Chao said continuous monitoring allows live assessment and more informed clinical decisions.

CeriBell, Inc. (NASDAQ:CBLL) is a commercial-stage medical technology firm that works to transform the diagnosis and treatment of pati

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/ceribell-inc-cbll-among-best-153131025.html)